Genomic profiles and prognostic biomarkers of resectable lung adenocarcinoma with a micropapillary component
Our study elucidates the unique genetic landscape of Chinese resectable LMPC patients and highlights high TMB and mutations in <i>SMARCA4</i>, SWI/SNF, and Nrf2 pathways as potential prognostic indicators in stage II-III disease. As these factors were not confirmed in multivariate models, they should be validated in larger, multi-center cohorts to guide future risk stratification and treatment decisions.
Authors
- Yan-yan Zhan (ORCID: https://orcid.org/0000-0003-3962-0349)
- Jiangshan Huang
- Wen-Wei Lin (ORCID: https://orcid.org/0000-0002-5144-6868)
- Yang Xu (ORCID: https://orcid.org/0000-0003-1670-6131)
- Junrong Yan (ORCID: https://orcid.org/0000-0001-9750-7518)
- Jiangbo Lin (ORCID: https://orcid.org/0000-0002-2405-5490)
- Jiafu Zhu
- Zhenyang Zhang (ORCID: https://orcid.org/0009-0000-2821-7736)
- Long Wu (ORCID: https://orcid.org/0000-0002-7710-3249)
- Xinhai Sun
- Yuane Lian
Institutions
- Fujian Medical University (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-29
- DOI
- https://doi.org/10.3389/fonc.2025.1574817
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52